1. Home
  2. ALT vs ALLT Comparison

ALT vs ALLT Comparison

Compare ALT & ALLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ALLT
  • Stock Information
  • Founded
  • ALT 1997
  • ALLT 1996
  • Country
  • ALT United States
  • ALLT Israel
  • Employees
  • ALT N/A
  • ALLT N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ALLT Telecommunications Equipment
  • Sector
  • ALT Health Care
  • ALLT Telecommunications
  • Exchange
  • ALT Nasdaq
  • ALLT Nasdaq
  • Market Cap
  • ALT 292.0M
  • ALLT 342.5M
  • IPO Year
  • ALT N/A
  • ALLT 2006
  • Fundamental
  • Price
  • ALT $3.83
  • ALLT $7.86
  • Analyst Decision
  • ALT Strong Buy
  • ALLT Buy
  • Analyst Count
  • ALT 6
  • ALLT 1
  • Target Price
  • ALT $17.40
  • ALLT N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • ALLT 535.2K
  • Earning Date
  • ALT 08-12-2025
  • ALLT 08-14-2025
  • Dividend Yield
  • ALT N/A
  • ALLT N/A
  • EPS Growth
  • ALT N/A
  • ALLT N/A
  • EPS
  • ALT N/A
  • ALLT N/A
  • Revenue
  • ALT $20,000.00
  • ALLT $95,342,000.00
  • Revenue This Year
  • ALT N/A
  • ALLT $10.64
  • Revenue Next Year
  • ALT $761,880.20
  • ALLT $15.76
  • P/E Ratio
  • ALT N/A
  • ALLT N/A
  • Revenue Growth
  • ALT N/A
  • ALLT 4.74
  • 52 Week Low
  • ALT $2.90
  • ALLT $2.75
  • 52 Week High
  • ALT $11.16
  • ALLT $10.77
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • ALLT 51.18
  • Support Level
  • ALT $3.35
  • ALLT $7.71
  • Resistance Level
  • ALT $3.66
  • ALLT $8.10
  • Average True Range (ATR)
  • ALT 0.19
  • ALLT 0.44
  • MACD
  • ALT 0.07
  • ALLT 0.09
  • Stochastic Oscillator
  • ALT 86.18
  • ALLT 59.12

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About ALLT Allot Ltd.

Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.

Share on Social Networks: